Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Clinical Trial, Phase II

Multicenter Study

Clinical Trial, Phase I

Research Support, Non-U.S. Gov't

Observational Study

Randomized Controlled Trial

Clinical Trial, Phase III

Comparative Study

Meta-Analysis

Systematic Review

Case Reports

Clinical Trial

Clinical Trial Protocol

Research Support, N.I.H., Extramural

Publication Year

From

Quick links

Individual year

2026

2025

2024

2018

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Polyether Polyketides""[mesh_terms]

23 Results

Searching titles within these results

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.

Akihito Kawazoe, Takao Takase, Takashi Oshima, Naotoshi Sugimoto, Hiroki Hara, Motohiro Hirao, Masahiro Tsuda, Yukinori Kurokawa, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Shuya Takashima, Taro Semba, Noboru Yamamoto, Hisato Kawakami, Kei Muro, Kensei Yamaguchi, Shota Kaname, Kaori Hino, Takeshi Kawakami

Clinical cancer research : an official journal of the American Association for Cancer Research 2024;30(7):1264-1272

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Polyether Polyketides""[mesh_terms]

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.

Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single-arm phase II trial.

Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.

Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.

Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.

Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.

Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma.

Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial).

The effects of the combination of temozolomide and Eribulin on T98G human glioblastoma cell line: an ultrastructural study.

Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.

Effect of stereochemistry at position C20 on the antiproliferative activity and selectivity of N-acylated derivatives of salinomycin.

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Results for
""Polyether Polyketides""[mesh_terms]